Several analysts have recently updated their ratings and price targets for ANI Pharmaceuticals (NASDAQ: ANIP):

  • 1/2/2018 – ANI Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN. “
  • 12/29/2017 – ANI Pharmaceuticals was given a new $77.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 12/21/2017 – ANI Pharmaceuticals was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 12/20/2017 – ANI Pharmaceuticals was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 12/9/2017 – ANI Pharmaceuticals was given a new $75.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 11/25/2017 – ANI Pharmaceuticals was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 11/16/2017 – ANI Pharmaceuticals was upgraded by analysts at TheStreet from a “c+” rating to a “b” rating.
  • 11/14/2017 – ANI Pharmaceuticals was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 11/7/2017 – ANI Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $71.00 price target on the stock. According to Zacks, “ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN. “

ANI Pharmaceuticals Inc (NASDAQ ANIP) opened at $72.41 on Friday. The company has a quick ratio of 2.39, a current ratio of 3.45 and a debt-to-equity ratio of 0.83. ANI Pharmaceuticals Inc has a 1 year low of $42.23 and a 1 year high of $74.70. The firm has a market cap of $843.07, a P/E ratio of 114.94 and a beta of 2.90.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $0.99 by $0.12. ANI Pharmaceuticals had a net margin of 4.45% and a return on equity of 22.40%. The firm had revenue of $48.16 million during the quarter, compared to analysts’ expectations of $48.12 million. During the same quarter in the previous year, the company posted $1.09 EPS. ANI Pharmaceuticals’s revenue was up 25.0% on a year-over-year basis. analysts expect that ANI Pharmaceuticals Inc will post 3.59 earnings per share for the current fiscal year.

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Receive News & Ratings for ANI Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.